VIDEO: IMbrave050 trial shows ‘exciting’ results in hepatocellular carcinoma
In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.
Kaseb, a professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, highlighted the study, which found increased recurrence-free survival of patients with hepatocellular carcinoma treated with adjuvant therapy with atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech), among a sample of high-risk patients selected on tumor size, number and differentiation.
“This study was exciting,” Kaseb said. “We really needed to look into some adjuvant studies, especially in this immunotherapy era.”
Collapse
Read more about